**ASX ANNOUNCEMENT**

13 February 2020

**CHIEF EXECUTIVE OFFICER UPDATE - REMUNERATION
AND FIRST TWO MONTHS AT THE HELM**

Respiri Limited (ASX:RSH) (“Respiri” or the “Company”) Following the announcement of 25 November 2019 the Company would like to confirm that Marjan Mikel commenced as its Chief Executive Officer on 2nd December 2019 having already been appointed a director on 25 November 2019.

The key terms of Marjan’s appointment as Managing Director and Chief Executive Officer of Respiri Limited are set out in Attachment 1 to this announcement.


Mr Nicholas Smedley, Executive Chairman of Respiri said, “Marjan has already made great inroads repositioning the company and its strategy for 2020. He has assembled a world class team - as outlined in the Company’s announcement of 31 January 2020 - with further appointments to be confirmed in the coming weeks.

Following the investor conference call held on 17 January 2020 and the eHealth SaaS announcement of 20 January 2020 Marjan has met face to face with a number of the Company’s investors to speak to his presentation and reiterate the objectives for 2020. The Company is confident that investors are now fully behind the Company’s new strategy and Marjan plans to implement it.”

Alastair Beard
Company Secretary
alastair@respiri.co

---End---

For personal use only

**Attachment 1****Key terms of Mr Marjan Mikel's employment agreement with the Company**

Commencement date as CEO	2 December 2019
Role	Managing Director and Chief Executive Officer
Term	Until terminated in accordance with the terms of the employment agreement.
Total Fixed remuneration	\$450,000 per annum, including compulsory superannuation.
At risk incentives	Nil, at this stage.
Notice period	Four weeks
Termination benefits	None beyond statutory entitlements and any portion of the notice that the CEO is not required to serve out.

About Respi Limited

Respi is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. The only platform of its kind, the flagship wheezo® product employs machine learning to provide personalised feedback and education based on the user's personal health data correlated with environmental factors, and enables the sharing of that data, anytime, anywhere with caregivers, physicians and other health care professionals.

Respi's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respi Limited's operations are based in Melbourne, Australia.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respi's current expectations, estimates and projections about the industry in which Respi operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respi, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respi cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respi only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respi will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.